09:54 AM EST - ProMetic Life Sciences Inc. : reported today that it has successfully completed its PBI-4050 Phase Ib multi-dose clinical trial in patients with chronic kidney disease. ProMetic's orally active lead drug candidate, PBI-4050, was found to be safe and well tolerated without any serious adverse events reported. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.05 at $2.80.
